Hill Holler

Raw Political Coverage and Opinions

Home /
Category: Health

Category: Health

Osteoporosis is a major risk illness that affects people whose bone density decreases at a faster rate than it forms. Life Line Screening offers extensive screening services to help diagnose the condition before it advances to an adverse state. The physicians use ultrasound technology to detect abnormal thickness or density in bones. They critically analyze the tibia and give a conclusive result to the patient. Life Line screening advises candidates at the risk of developing osteoporosis to undergo a screening test at least once a year.

Statistics indicate that osteoporosis is a condition that affects millions of people across the world each year. The United States’ medical reports indicate that at least two million people suffer from broken bones every year. The medical resources and services used to attend to the patients total up to around $19 billion. Medical analysts estimate that the price will skyrocket to $25.3 billion in only eight years. The most expensive tool used in scanning bone density is the DXA X-Ray machine.

Life Line Screening has collaborated with Europe’s most prominent manufacturer of medical devices to heighten the efficiency of their services. Bone Index Limited is a top provider of medical technology and will be servicing Life Line Screening with innovative tools for various purposes. The firm’s Bindex point of care machine calculates the bone’s thickness while the embedded algorithm calculates the density index. Density at the hip is measured using the DXA tool.

The chief executive officer of Bone Index remarked that Life Line Screening would receive exponential services to help in all the screening events they host on an annual basis. Life Line Screening hosts approximately 15,000 events per year across the States. They test for indications of vascular abnormities and odd bone densities. The vice president of Life Line Screening seconded that remark by stating that Bone Index has privileged them with an opportunity to heighten the quality of their work and ultimately improve the lives of Americans. He is confident that Life Line Screening will be an exceptional firm in offering the best services in the industry.

The CEO of Bindex added that his company was enthusiastic to begin working with Life Line Screening. Bindex has 19 active patents in Europe, Japan, Chin and the United States. The firm has earned a name as a remarkable manufacture of medical tech and currently leads in osteoporosis screening in Finland. Life Line Screening revealed that they have an aim to foster a long-term relationship with the firm.

Learn More: en.wikipedia.org/wiki/Life_Line_Screening

Amicus Therapeutics has its headquarters office in Cranbury, New Jersey. The international headquarters office of Amicus is located in the United Kingdom. The other locations of Amicus Therapeutics are located in France, Germany, Italy, Netherlands, and Spain. It became a publicly traded company in 2007. The stock symbol of Amicus is FOLD. Amicus is traded on the NASDAQ market. The company was established in February 4, 2002. John F. Crowley has been the CEO of Amicus Therapeutics since 2005. Bradley Campbell is the Chief Operating Officer. William “Chip” Baird is the Chief Financial Officer. As of December 31, 2013, there were 92 employees at Amicus Therapeutics (YahooFinance).


The therapies offered by this pharmaceutical company focus on the care of rare and orphan diseases, such as lysosomal storage disorders (LSDs). SD-101 was developed for the treatment of Epidermolysis Bullosa (EB), a rare tissue disease that causes skin blistering. Migalastat was created for treating Fabry disease. It stabilizes the alpha-Gal A produced in the patient’s cells so it can be moved to the lysosomes. When it gets to the lysosomes, the GL-3 could be reduced. The brand name for Migalastat is Galafold. In order to develop enzyme replacement technologies(ERTs), Amicus Therapeutics leverages the Chaperone-Advanced Replacement Therapy (CHART) technology. Also, CHARTs are used to make ATB200/AT222, a treatment method consisting of a recombinant human acid alpha-glucosidase (rhGAA) enzyme. Therefore, Pompe disease can be treated with ATB200/AT222 because the deficiency of GAA is eliminated with rhGAA enzymes. As of right now, Amicus Therapeutics is discovering a new protein replacement therapy for CDKL5 (cyclin-dependent kinase-like 5) deficiency.


The company uses contractors for manufacturing because it is not an independent manufacturer. Amicus Therapeutics bought Callidus Biopharma in November 2013 (https://forexwizard.biz/2017/09/15/amicus-therapeutics/). As a result of the acquisition, Amicus had access to proprietary items and intellectual property that would be useful for the enzyme replacement technology used in treating Pompe Disease. The company made another acquisition in September 2015. This time it bought Scioderm for $947 million. CabaRare is a festival hosted by Amicus to celebrate RareDisease day. Performers with rare diseases participate in this festival.

More on Twitter

Clay Siegall Ph.D. is a man with an impressive and inspiring story of achievements, and dedication. He is the co-founder, CEO, and chairman of Seattle Genetics, which has been in business since 1998. He saw his father battle cancer and eventually succumb to it, which is why he dedicated himself to fighting cancer. While studying at the University of Maryland, his advisers shared a curiosity about cancer treatment. This background explains how he considered a path towards research. An internship at the National Institute of Health opened up a pathway to his goal. He later attended George Washington University to pursue his Ph.D.


Clay founded Seattle Genetics with a vision of developing innovative biotechnological research with the aim of helping patients. The company has several licenses including with Pfizer. Under the leadership of Dr. Siegall, the company has generated more than $1.2 billion through public and private funding. The funding has allowed the company to continue to be a trail blazer in advancing cancer treatment through innovative technology.


Clay’s scientific mind and visionary leadership make him a rare individual. He is propelling his company and also the entire industry to new heights. Under Dr. Clay Siegall, the company has entered into multiple strategic licenses for their ADC technology. The move has, in turn, made them industry leaders in the field of antibody drug conjugates. With the FDA approval of the companies first ADC product, Adcentris, the company has generated more than $350 million in sales to date. The drug is now approved in more than 65 countries, adding to Clay’s success.


Imagine going to work every day and seeing the people who the drug you developed has saved. It is a fantastic atmosphere to work. Dr. Siegall is looking more determined every day, and the individuals who are working with him are motivated to do more to help the patients. The inspiring atmosphere at Seattle Genetics makes for the perfect conditions to pursue the fight against cancer. Dr. Siegall currently holds 15 patents and is always pushing the boundaries to better treatment. He has published more than 70 publications to contribute to the medical and scientific community.